Regorafenib in Advanced and Refractory Gastrointestinal Cancers - Symposium - EMJ

Regorafenib in Advanced and Refractory Gastrointestinal Cancers

Gastroenterology
Download PDF
Speakers:
Eric Van Cutsem,1 Michael Ducreux,2 Diether Lambrechts3
Disclosure:

Prof Eric Van Cutsem has received research funding from Amgen, Bayer, Boehringer Ingelheim, Lilly, Merck Serono, Novartis, Roche, and Sanofi. Dr Diether Lambrechts has served on advisory boards for Roche, Sanofi, Bayer, and Boehringer-Ingelheim, and received speaker’s fees from Eli Lilly and Roche. Dr Michel Ducreux has received research funding from Roche, Chugai, and Pfizer, and has other substantive relationships with Celgene, Merck Serono, Amgen, Novartis, and Sanofi.

Acknowledgements:

Medical writing was provided by Ewen Legg, PhD, of Halcyon Medical Writing and was funded by Bayer.

Support:

Medical writing was provided by Ewen Legg, PhD, of Halcyon Medical Writing and was funded by Bayer.

Citation:
EMJ. ;1[3]:21-25. DOI/10.33590/emj/10311556. https://doi.org/10.33590/emj/10311556.
Keywords:
ESMO, European Society of Medical Oncology, WCGI, World Congress on Gastrointestinal Cancer

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The European Society for Medical Oncology’s (ESMO) 18th World Congress on Gastrointestinal Cancer (WCGI) was held in Barcelona from 28th June–2nd July 2016. Presentations covered gastrointestinal (GI) cancers of every aetiology and site within the GI tract, as well as the major aspects of cancer management from screening to novel therapeutic options. Tyrosine kinase inhibitors (TKIs), with their ability to block key mechanisms required for tumour growth, featured heavily in this year’s presentations at WCGI. Data on the oral TKI regorafenib featured prominently in both poster discussion tours and oral presentations, emphasising the continuing interest in the evolution of this therapy within the clinical arsenal of physicians tackling GI cancers.

Please view the full content in the pdf above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>